Madrigal Pharmaceuticals Inc (MDGL)

NASDAQ
131.61
-1.10(-0.83%)
  • Volume:
    73,964
  • Bid/Ask:
    114.00/1,141.00
  • Day's Range:
    131.02 - 136.40

MDGL Overview

Prev. Close
132.71
Day's Range
131.02 - 136.4
Revenue
-
Open
133.48
52 wk Range
97 - 142.62
EPS
-14.07
Volume
73,964
Market Cap
2.18B
Dividend (Yield)
N/A (N/A)
Average Vol. (3m)
127,161
P/E Ratio
-
Beta
1.08
1-Year Change
15.63%
Shares Outstanding
16,584,625
Next Earnings Date
Aug 12, 2021
What is your sentiment on Madrigal Pharmaceuticals Inc?
or
Market is currently closed. Voting is open during market hours.

Madrigal Pharmaceuticals Inc News

Madrigal Pharmaceuticals Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellSellBuyStrong Buy
Technical IndicatorsStrong SellStrong SellStrong SellBuyStrong Buy
SummaryStrong SellStrong SellStrong SellBuyStrong Buy

Madrigal Pharmaceuticals Inc Company Profile

Madrigal Pharmaceuticals Inc Company Profile

Employees
42

Madrigal Pharmaceuticals, Inc., formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company's lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH). Its product pipeline also includes MGL-3745, which is used in the treatment of NASH and FH. MGL-3196 has completed Phase I single and multiple dose trials in healthy volunteers. MGL-3196 is being developed for dyslipidemia/hypercholesterolemia to lower low-density lipoproteins cholesterol, triglyceride levels and lipoprotein(a). MGL-3196 also reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.

Read More
  • +23% from lows a few days ago... -3.23% from SMA50 and -5.25% from SMA200... Short ratio 12+, that means 12+ days for short sellers to cover... with 90%+ institutional ownership it is a matter of days before short sellers will be burnt ugly.. 100$ and then 120$ are the first targets.. ride the train and good luck!
    0
    • $MDGL Buy this puppy before MGL-3196 phase 3 initiation.. NASH is hottest thing after slice of bread.
      1
      • no worries parent company would save the day
        0
        • "Signs of things to come"...
          0
          • hallo anybody there? xD
            1
            Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
            Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.